MYD88 and neoplasm: Although recently developed allele-specific polymerase chain reaction (AS-PCR) is highly sensitive in determining the MYD88 L265P status and its quantitative assessment may be utilized in monitoring tumor burden [9], CD19-selection technique is required to achieve enough sensitivity when peripheral blood (PB) is used [7], which may not be suitable for clinical use.